Skip to main navigation Skip to search Skip to main content

Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism

  • Varun V. Prabhu
  • , Neel S. Madhukar
  • , Coryandar Gilvary
  • , C. B. Leah Kline
  • , Sophie Oster
  • , Wafik S. El-Deiry
  • , Olivier Elemento
  • , Faye Doherty
  • , Alexander VanEngelenburg
  • , Jessica Durrant
  • , Rohinton S. Tarapore
  • , Sean Deacon
  • , Neil Charter
  • , Jinkyu Jung
  • , Deric M. Park
  • , Mark R. Gilbert
  • , Jessica Rusert
  • , Robert Wechsler-Reya
  • , Isabel Arrillaga-Romany
  • , Tracy T. Batchelor
  • Patrick Y. Wen, Wolfgang Oster, Joshua E. Allen
  • Oncoceutics, Inc.
  • Cornell University
  • Fox Chase Cancer Center
  • Inc.
  • Eurofins GSC Lux SARL
  • National Institutes of Health
  • Sanford Burnham Prebys Medical Discovery Institute
  • Massachusetts General Hospital
  • Dana-Farber Cancer Institute

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Abstract

Purpose: Dopamine receptor D2 (DRD2) is a G protein–coupled receptor antagonized by ONC201, an anticancer small molecule in clinical trials for high-grade gliomas and other malignancies. DRD5 is a dopamine receptor family member that opposes DRD2 signaling. We investigated the expression of these dopamine receptors in cancer and their influence on tumor cell sensitivity to ONC201. Experimental Design: The Cancer Genome Atlas was used to determine DRD2/DRD5 expression broadly across human cancers. Cell viability assays were performed with ONC201 in >1,000 Genomic of Drug Sensitivity in Cancer and NCI60 cell lines. IHC staining of DRD2/DRD5 was performed on tissue microarrays and archival tumor tissues of glioblastoma patients treated with ONC201. Whole exome sequencing was performed in RKO cells with and without acquired ONC201 resistance. Wild-type and mutant DRD5 constructs were generated for overexpression studies. Results: DRD2 overexpression broadly occurs across tumor types and is associated with a poor prognosis. Whole exome sequencing of cancer cells with acquired resistance to ONC201 revealed a de novo Q366R mutation in the DRD5 gene. Expression of Q366R DRD5 was sufficient to induce tumor cell apoptosis, consistent with a gain-of-function. DRD5 overexpression in glioblastoma cells enhanced DRD2/DRD5 heterodimers and DRD5 expression was inversely correlated with innate tumor cell sensitivity to ONC201. Investigation of archival tumor samples from patients with recurrent glioblastoma treated with ONC201 revealed that low DRD5 expression was associated with relatively superior clinical outcomes. Conclusions: These results implicate DRD5 as a negative regulator of DRD2 signaling and tumor sensitivity to ONC201 DRD2 antagonism.

Original languageEnglish
Pages (from-to)2305-2313
Number of pages9
JournalClinical Cancer Research
Volume25
Issue number7
DOIs
StatePublished - 1 Apr 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism'. Together they form a unique fingerprint.

Cite this